Altimmune reported a net loss of $22.8 million, or $0.12 per share, for the second quarter ended June 30, 2026, compared to a $22.1 million loss in the prior year period. The company held $519 million in cash and investments as of June 30, 2026. Key clinical milestones included initiating the global Phase 3 PERFORMA trial for MASH, reporting positive topline data from the Phase 2 RECLAIM trial in AUD, and completing enrollment in the Phase 2 RESTORE trial for ALD. R&D expenses rose to $18.7 million due to startup costs for the PERFORMA trial and ongoing ALD work, while G&A expenses increased to $7.6 million. Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide for serious liver diseases.
